ABSI

Absci Corp

ABSI.US absci.com
8.24
-0.41 (-4.74%)
USD · NASDAQ
52-week range
2.24
12.06
Trading at 61% of the 52-week range
Market Cap
1.48B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.44
Div. Yield
N/A
% Institutions
87.10%
% Insiders
11.84%

1 Year

+246.2%

3 Year

+396.4%

10 Year

-61.8%
Description

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Company Information

Company Name
Absci Corp
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00091E1091
CIK: 0001672688
CUSIP: 00091E109
Currency: USD
Full Time Employees: 140
Phone: 360 949 1041
Website: absci.com
Fiscal Year End: December
IPO Date: Jul 22, 2021
Description:

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Address:

18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683

People

Directors & Officers

Name Title Year Born
Mr. Sean McClain Founder, CEO, President & Director 1990
Dr. Zachariah Jonasson Ph.D. Chief Business Officer & CFO 1973
Mr. Todd Bedrick CPA Senior VP & Chief Accounting Officer NA
Mr. Alexander Khan CPA CVP of Finance & Head of Investor Relations NA
Ms. Shelby Walker J.D. Chief Legal Officer 1975
Ms. Jeanne Schreuder M.B.A., SPHR Senior Vice President of People & Experience NA
Mr. Wen Sha Chief of Staff NA
Dr. Christine Lemke D.V.M., M.B.A., Ph.D. Senior Vice President of Portfolio & Growth Strategy NA
Dr. Ransi Somaratne FACC, M.B.A., M.D. Chief Medical Officer 1966
Dr. Moetaz B. Albizem M.D. Senior Vice President of Clinical Operations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 12, 2026 Andreas Busch N/A Purchase 100.00K $2.29 $229.00K
Feb 02, 2026 Sean Mcclain N/A Sale 26.76K $2.99 $80.02K
Sep 22, 2025 Menelas N Pangalos N/A Purchase 95.79K $2.66 $254.79K
Sep 22, 2025 Todd Bedrick N/A Purchase 10.00K $2.70 $27.00K
Jul 28, 2025 Andreas Busch N/A Purchase 50.00K $3.04 $152.00K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 22.55M Mar 31, 2026 13.14% $0.00 0.76%
ARK Investment Management LLC 13.73M Mar 31, 2026 8.00% $0.32 9.36%
BlackRock Inc 11.26M Mar 31, 2026 6.56% $0.00 -0.69%
State Street Corp 7.32M Mar 31, 2026 4.27% $0.00 22.27%
Redmile Group, LLC 6.74M Jun 30, 2026 3.93% $5.24 -18.34%
Vanguard Capital Management, LLC 5.89M Mar 31, 2026 3.43% $0.00 0.00%
Advanced Micro Devices Inc 5.71M Jun 30, 2026 3.33% $5.05 0.00%
Adage Capital Partners Gp LLC 5.70M Jun 30, 2026 3.32% $0.09 0.00%
D. E. Shaw & Co LP 5.24M Jun 30, 2026 3.05% $0.03 706.34%
Geode Capital Management, LLC 3.34M Mar 31, 2026 1.95% $0.00 3.19%
Woodline Partners LP 3.30M Mar 31, 2026 1.92% $0.04 44.69%
Ameriprise Financial Inc 3.18M Mar 31, 2026 1.85% $0.00 -0.51%
Two Sigma Investments LLC 2.90M Mar 31, 2026 1.69% $0.01 104.37%
Gem Investment Advisors, LLC 2.17M Jun 30, 2026 1.27% $15.43 0.00%
Baker Bros Advisors LP 2.13M Mar 31, 2026 1.24% $0.04 0.00%
Siren, L.L.C. 1.80M Mar 31, 2026 1.05% $0.15 0.00%
Massachusetts Financial Services Company 1.72M Mar 31, 2026 1.00% $0.00 0.01%
UBS Group AG 1.60M Mar 31, 2026 0.93% $0.00 -40.74%
Amova Asset Management Americas, Inc 1.35M Mar 31, 2026 0.78% $0.06 -5.47%
Marshall Wace Asset Management Ltd 1.22M Mar 31, 2026 0.71% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 11.29M 6.58% ▲ 0.00% Jul 31, 2026
2 ARK Genomic Revolution ETF 10.90M 6.35% ▼ 0.35% Aug 31, 2026
3 ARK Genomic Revolution 10.23M 5.96% ▼ 8.69% Jun 30, 2026
4 Fidelity Growth Company Fund 7.90M 4.61% ▲ 0.00% Jul 31, 2026
5 State Street® SPDR® S&P® Biotech ETF 5.46M 3.18% ▼ 1.06% Aug 31, 2026
6 Vanguard MStar Total Stk Mkt Idx Invest 4.46M 2.60% ▲ 1.25% Jul 31, 2026
7 iShares Russell 2000 ETF 3.53M 2.06% ▼ 0.57% Aug 31, 2026
8 ARK Venture D 3.01M 1.76% ▲ 169.80% Apr 30, 2026
9 Fidelity Growth Company K6 2.47M 1.44% ▲ 0.00% Jul 31, 2026
10 Columbia Small Cap Growth 2.27M 1.32% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $1.48B
EBITDA: $-119.51M
Book Value: $1.44
Earnings/Share: $-0.77
Profit Margin: 0.00%
Operating Margin: -10,741.51%
ROA (TTM): -34.10%
ROE (TTM): -57.72%
Revenue (TTM): $1.56M
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -46.40%

Valuation Metrics

Enterprise Value: $1.33B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 171.61M
Shares Float: 163.79M
% Insiders: 11.84%
% Institutions: 87.10%
Short % Float: 26.53%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$2.80M
Cost of Goods Sold
adjust
$-11.74M
Gross Profit
subtotal
$-8.94M
SG&A
adjust
$-35.06M
R&D
adjust
$-81.42M
Operating Income
subtotal
$-124.72M
Other / Non-Operating Items
adjust
$9.54M
Net Income
subtotal
$-115.18M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ABSI.US!